PDF Cover

Lusutrombopag Market

Lusutrombopag Market

The market for Lusutrombopag was estimated at $221 million in 2024; it is anticipated to increase to $326 million by 2030, with projections indicating growth to around $451 million by 2035.

Report ID:DS1802316
Author:Debadatta Patel - Senior Consultant
Published Date:May 2025
Datatree
Life Science
Pharmaceutical
Lusutrombopag
Share
Report Summary
Table of Contents
Methodology
Market Data

Global Lusutrombopag Market Outlook

Revenue, 2024

$221M

Forecast, 2034

$423M

CAGR, 2024 - 2034

6.7%
The Lusutrombopag industry revenue is expected to be around $236.0 million in 2025 and expected to showcase growth with 6.7% CAGR between 2025 and 2034. The growing demand for Lusutrompbopag in the market can be linked to factors like the increase in thromboctopenia cases in patients with chronic liver diseases and the rising use it for treating this ailment. Lusutrompbopag has shown its effectiveness through trials and benefits from significant research and advancements in pharmaceutical technology which has made it a key player, in various treatment scenarios. Moreover the presenceof pertinent medical conditions, escalating clinical urgency and the rise in healthcare expenditures worldwide particularly in developed and emerging economies have played a crucial role, in solidifying the ongoing market importanceof Lusutromboag.

The medication Lusutrommopab is mainly prescribed for treating platelet count in individuals with long term liver issues who are undergoing medical procedures. It functions by attaching to and stimulating the receptor in humans resultig in a rise in platelet production, within the body.

Lusutrombopag market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034

Market Key Insights

  • The Lusutrombopag market is projected to grow from $221.2 million in 2024 to $423 million in 2034. This represents a CAGR of 6.7%, reflecting rising demand across Chronic Liver Diseases Treatment, Thrombocytopenia Management and Post-transplant Care.
  • Shionogi & Co Ltd., Novartis International AG, Takeda Pharmaceutical Company Limited are among the leading players in this market, shaping its competitive landscape.
  • U.S. and Japan are the top markets within the Lusutrombopag market and are expected to observe the growth CAGR of 4.4% to 6.4% between 2024 and 2030.
  • Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 7.7% to 9.2%.
  • Transition like Emergence of Tailored Therapies is expected to add $30.1 million to the Lusutrombopag market growth by 2030
  • The Lusutrombopag market is set to add $202 million between 2024 and 2034, with manufacturer targeting Thrombocytopenia & Hepatology Disorders Disease Application projected to gain a larger market share.
  • With Increasing prevalence of liver diseases, and Unmet medical needs for safe thrombopoietin receptor agonist, Lusutrombopag market to expand 91% between 2024 and 2034.
lusutrombopag market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032

Opportunities in the Lusutrombopag

Collaborating with partners can help multinational pharmaceutical companies like LUSUTROMBOPAG grow their market presence successfully in regions with strict regulations, through strategic partnerships and effective market penetration strategies.

Growth Opportunities in North America and Asia Pacific

North America Outlook

Consistently leading the market is North America. Primarily the United States. Which holds a firm grip on the Lusutromabopag sector due to its prominent healthcare industry and strong research and development capabilities. This growth is propelled by pharmaceutical companies that are both increasing the need for and providing the supply for Lusutromabopag. The market is further boosted by stroke patients who are contributing to the demand, for this receptor agonist. Competition in North America is strong as manufacturers from Asia Pacific and Europe aim to establish their presence in the Lusutrombo market. Factors driving this industry include increased awareness about thromboy openia among the public and the convenience of medication, for patients which improves acceptance and adherence.

Asia Pacific Outlook

The Asia Pacific region is establishing itself as a player in the production and use of Lutrombo pag products with countries like Japan and South Korea leading the way in rapid market growth due to several factors such as an aging population and rising cases of liver related conditions causing low platelet counts alongside advancements in healthcare services overall Government efforts to improve pharmaceutical manufacturing also play a vital role, in driving growth in this region.

Market Dynamics and Supply Chain

01

Driver: Increasing Prevalence of Liver Diseases, and Growing Research and Development Activities

The rising numbers of liver illnesses around the world have also brought attention to the use of Lusutromabpag as a treatment for conditions such as liver disease and cirrhosis that can also result in reduced platelet levels in the blood stream. The growing investment in healthcare for liver diseases is also a factor driving the market for Lusutromabpag due to its effectiveness, in boosting platelet counts in adults dealing with chronic liver disease. There has also been an increase in partnerships and collaborations within the pharmaceutical industry to create and bring new thromobopoietin receptor agonist drugs to market forming a new segment, in the industry.
Patients with long term liver conditions who experience platelet counts commonly undergo procedures that involve some level of risk for bleeding complications. Leveraging its ability to mitigate these risks has also positioned Lutrombobap as a favored treatment option among thromboptopoeitin receptor agonists because it is also known for being both safe and effective in addressing an existing gap in care. This has also led to an increase in its market demand due to its success, in aiding patients preparing for procedures.
02

Restraint: Regulatory Challenges

Despite the research and urgent need in the medical field for Lusutromabopags potential benefits to patients well being and health conditions; its availability in the market may face challenges due to rigorous regulatory protocols that demand thorough testing and clinical trials to ensure its safety and effectiveness for public consumption. This process is often burdened with approval timelines and substantial costs which can impede the expansion in the market and influence the dynamics within the healthcare industry. For instance if Lusutromabopag encounters delays or obstacles in meeting requirements for approval, in specific regions or countries; this could create bottlenecks affecting its availability to those who might benefit from it. These regulatory challenges frequently require investment, with no assurance of outcomes and may impede market advancement.
03

Opportunity: Untapped Segments and Technological Innovations

The potential benefits that Lusutromabpag offers in managing thromcytopenia. A condition marked by platelet levels. Especially among individuals with chronic liver issues undergoing invasive treatments are notable. The promising performance of this medication and the increasing prevalence worldwide of liver ailments indicate an opportunity for expansion in an underexplored market segment. Nations with rates of liver diseases, like China and India might offer profitable business prospects.
Lusutromboapg is an option in treating thrombosytopenia that could see improvements through continued pharmaceutical research and technological advancements in delivery methods and formulations. Progress in pharmaceuticals focusing on increasing drug effectiveness and minimizing side effects to boost adherence could lead to substantial growth, in the market.
04

Challenge: High Treatment Costs

The high price tag attached to Lusutromabopag treatment is another factor to consider in the market landscape due, to the research and development expenses typically associated with new drugs.

Supply Chain Landscape

1
Raw Material Procurement

Eisai Co. Ltd

Takeda Pharmaceutical Company

2
API Production

Shionogi & Co. Ltd

Eisai Co. Ltd

3
Formulation & Packaging

Takeda Pharmaceutical Company

Shionogi & Co. Ltd

4
Distribution & End-User

Specialty Pharmacy

Hospital Pharmacy

Retail Pharmacy

*The illustration highlights the key stakeholders within the supply chain ecosystem.

Applications of Lusutrombopag in Chronic Liver Diseases Treatment, Thrombocytopenia Management & Post-transplant Care

Chronic Liver Diseases Treatment

The drug Lusutromborgopag is commonly used to treat liver diseases as it helps boost the production and count platelets in the blood. Especially crucial in cases like hepatitis C where platelet levels drop significantly. This medication is supplied by the known pharmaceutical company Shionogi & Co. which has a dominant presence, in providing Lusutromborgopag for this particular health condition.

Thrombocytopenia Management

Another frequent use for Lusutrombp is in handling Thromocytopenia cases by enhancing platelet levels and lessening the requirement for transfusions in patients with low platelet count who are undergoing invasive procedures. Novartis has a history, in improving the treatment outcomes for this condition through the use Lusutrombp.

Post-transplant Care

In transplant care for patients who have undergone liver transplants due to conditions like Hepatitis B and experience low platelet counts as a result Lusutromopag is now being used more frequently. By using Lusutromopag in this context platelet production is encouraged, which helps reduce the likelihoods of bleeding episodes and other complications. Gilead Sciences, a participant in this sector is actively researching and advocating for the utilization of Lututromopag, in post transplant care environments.

Recent Developments

December 2024

Shinogi Inc., a producer in the pharmaceutical industry for Lusutrombobap medication officially received FDA endorsement for a fresh application in pediatrics. This move expands its market reach. Provides innovative therapy choices, for children suffering from thromboyctopenia.

October 2024

Novartis Pharmaceuticals showed promising outcomes in a phase III study that compared Lusutrom bop ag with alternative throm Bop Oietin receptor activators. These findings suggest effectiveness and safety features and pave the way, for potential joint treatment options.

August 2024

Shionogi Inc.

garner heightened attention and utilization, within the pharmaceutical sector is Lusutrom bopag—a new medication originally authorized for addressing throm bocytopenia; a medical predicament characterized by diminished blood platelet levels. Lusutrom bopag operates by influencing the thrombo poietin receptor to stimulate platelet generation.

Impact of Industry Transitions on the Lusutrombopag Market

As a core segment of the Pharmaceutical industry, the Lusutrombopag market develops in line with broader industry shifts. Over recent years, transitions such as Emergence of Tailored Therapies and Rise in Biomedical Research have redefined priorities across the Pharmaceutical sector, influencing how the Lusutrombopag market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Emergence of Tailored Therapies

The field of biotechnology has seen a shift towards creating personalized treatments lately. The emergence of Lusutrombopag stands out as an example tailored for adults dealing with chronic liver conditions. This development showcases how pharmaceutical companies have met a demand that was previously unaddressed, utilizing the characteristics of this compound. This evolution has not only led to better results for patients but has also spurred economic expansion, in healthcare through the introduction of specialized treatments that come with higher price tags. The costs associated with hospital stays and managing illnesses have significantly decreased due to the proven effectiveness Lusutromtopag has shown in treating thromobocytopenia. This move, towards tailored medical care highlights the promise that individualized healthcare solutions hold for patients. This industry transition is expected to add $30.1 million in the industry revenue between 2024 and 2030.
02

Rise in Biomedical Research

There has been a shift in the industry towards emphasizing biomedical research particularly in the pharmaceutical and biotechnology fields with a growing dedication to advancing groundbreaking drugs such, as Lusutrombo pag.

Related Reports

Loading related reports...